Sucampo Pharmaceuticals (SCMP) was Downgraded by Mizuho to ” Neutral” and the brokerage firm has set the Price Target at $13. Earlier the firm had a rating of “Buy ” on the company shares. Mizuho advised their investors in a research report released on Aug 4, 2016.
Many Wall Street Analysts have commented on Sucampo Pharmaceuticals. Shares were Reiterated by Maxim Group on Aug 1, 2016 to “Buy” and Lowered the Price Target to $ 17 from a previous price target of $26 .
On the company’s financial health, Sucampo Pharmaceuticals reported $0.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $0.21. The company had revenue of $52.00 million for the quarter, compared to analysts expectations of $48.09 million. The company’s revenue was up 49.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 EPS.
Sucampo Pharmaceuticals closed down -0.23 points or -1.93% at $11.66 with 4,34,040 shares getting traded on Tusday. Post opening the session at $11.88, the shares hit an intraday low of $11.56 and an intraday high of $11.95 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Nov 18, 2015, Andrew P Smith (CFO) purchased 1,605 shares at $17.03 per share price. According to the SEC, on Aug 31, 2015, Daniel P Getman (director) sold 30,000 shares at $28.14 per share price. On Mar 18, 2015, Anthony C. Celeste (director) sold 65,966 shares at $17.34 per share price, according to the Form-4 filing with the securities and exchange commission.
Sucampo Pharmaceuticals Inc. is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal ophthalmic and oncology-based inflammatory disorders. It generates revenue from product royalties development milestone payments product sales and clinical development activities. Its operations are conducted through Sucampo AG (SAG) based in Zug Switzerland through which the Company conducts certain worldwide and European operations; Sucampo Pharma LLC based in Tokyo and Osaka Japan through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC based in Bethesda through which the Company conducts operations in North and South America and Sucampo Pharma Europe Ltd. based in Oxford United Kingdom. The Company’s geographic segments are Asia the Americas and Europe.